Top

Published in:

01-11-2006 | Original Article

Genetic susceptibility to Parkinson’s disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker

Authors: Ramesh C. Juyal, Mitashree Das, Sohan Punia, Madhuri Behari, Geetika Nainwal, Sumit Singh, Pazhayannur V. Swaminath, Shyla T. Govindappa, Sachi Jayaram, Uday B. Muthane, B. K Thelma

Published in: Neurogenetics | Issue 4/2006

Abstract

The depletion of dopamine levels in the brain due to degeneration of dopaminergic neurons of substantia nigra pars compacta is a hallmark of Parkinson’s disease (PD). The cumulative contribution of genetic variations in genes from the dopaminergic pathway has been widely implicated to confer susceptibility to idiopathic PD. We present in this paper an extensive association analysis of a total of 20 markers including single nucleotide polymorphism/short tandem repeat/variable number tandem repeat/duplication markers from five candidate genes (namely, dopamine receptors DRD1, DRD2, DRD3, and DRD4, and dopamine transporter) with PD among two independent sample sets. The allelic, genotypic, and haplotypic association of these markers with PD was tested in South Indian (SI) samples (147 cases, 130 controls) and replicated in a larger North Indian (NI) sample set (340 cases, 344 controls). Of the several markers analyzed, 120 bp duplication marker of DRD4 gene showed promising results with PD in both of the sample sets. A significant allelic association in SI [odds ratio, OR (95% confidence interval, CI)=0.67 (0.47–0.97) for 120 bp dup; 1.48 (1.03–2.13) for 120 bp WT] and genotypic association in SI [OR (95% CI)= 0.56 (0.35–0.91) for 120 bp dup/dup; 1.62 (0.99–2.64) for 120 bp dup/120 bp WT] and in NI [OR (95% CI)= 1.41 (1.03–1.93) for 120 bp dup/ 120 bp WT] was observed. This is the first report on the association of dopaminergic gene polymorphisms with PD from the Indian sub-continent.

Available only for authorised users

de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(1):10–15PubMedCrossRef

Huang Y, Cheung L, Rowe D, Halliday G (2004) Genetic contributions to Parkinson’s disease. Brain Res Brain Res Rev 46(1):44–70PubMedCrossRef

Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302(5646):819–822PubMedCrossRef

Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047PubMedCrossRef

Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608PubMedCrossRef

Leroy E, Boyer R, Auburger G et al (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395(6701):451–452PubMedCrossRef

Bonifati V, Rizzu P, van Baren MJ et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604):256–259PubMedCrossRef

Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160PubMedCrossRef

Paisan-Ruiz C, Jain S, Evans EW et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600PubMedCrossRef

10.

Snyder SH, D’Amato RJ (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson’s disease The 1985 George C Cotzias lecture. Neurology 36(2):250–258PubMed

11.

Williams A, Waring R (1993) The MPTP tale: pathway to prevention of Parkinson’s disease? Br J Hosp Med 49(10):716–719PubMed

12.

Prasad KN, Cole WC, Kumar B (1999) Multiple antioxidants in the prevention and treatment of Parkinson’s disease. J Am Coll Nutr 18(5):413–423PubMed

13.

Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111(2):163–169PubMedCrossRef

14.

Kidd PM (2000) Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 5(6):502–529PubMed

15.

Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998) Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S89–S98PubMed

16.

Kosel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB (1999) Role of mitochondria in Parkinson disease. Biol Chem 380(7–8):865–870PubMedCrossRef

17.

Rubinstein M, Phillips TJ, Bunzow JR et al (1997) Mice lacking dopamine D4 receptors are supersensitive to ethanol cocaine and methamphetamine. Cell 90(6):991–1001PubMedCrossRef

18.

Oliveri RL, Annesi G, Zappia M et al (2000) The dopamine D2 receptor gene is a susceptibility locus for Parkinson’s disease. Mov Disord (1):127–131

19.

Tan EK, Tan Y, Chai A et al (2003) Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson’s disease. Mov Disord 18(5):593–595PubMedCrossRef

20.

Ricketts MH, Hamer RM, Manowitz P, Feng F, Sage JI, Di Paola R, Menza MA (1998) Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson’s disease. Clin Genet 54(1):33–38PubMedCrossRef

21.

Wan DC, Law LK, Ip DT, Cheung WT, Ho WK, Tsim KW, Kay R, Woo J, Pang CP (1999) Lack of allelic association of dopamine D4 receptor gene polymorphisms with Parkinson’s disease in a Chinese population. Mov Disord 14(2):225–229PubMedCrossRef

22.

Grondin R, Doan VD, Gregoire L, Bedard PJ (1999) D1 receptor blockade improves l-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52(4):771–776PubMed

23.

Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (2001) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347(6289):146–151CrossRef

24.

Zappia M, Annesi G, Quattrone A (2002) Association study of dopamine D2 D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 58(5):837PubMed

25.

Wang J, Zhao C, Chen B, Liu ZL (2004) Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson’s disease. Neurosci Lett 355(3):193–196PubMedCrossRef

26.

Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, Thelma BK (2006) Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: ÉV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 16(2):111–117PubMedCrossRef

27.

Accili D, Fishburn CS, Drago J et al (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93(5):1945–1949PubMedCrossRef

28.

Mercier G, Turpin JC, Lucotte G (1999) Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson’s disease: no association found. J Neurol 246(1):45–47PubMedCrossRef

29.

Lin JJ, Yueh KC, Chang DC, Chang CY, Yeh YH, Lin SZ (2003) The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson’s disease for male but not to female patients. J Neurol Sci 209(1–2):87–92PubMedCrossRef

30.

Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184PubMedCrossRef

31.

Sato M, Soma M, Nakayama T, Kanmatsuse K (2000) Dopamine D1 receptor gene polymorphism is associated with essential hypertension. Hypertension 36(2):183–186PubMed

32.

Itokawa M, Arinami T, Futamura N, Hamaguchi H, Toru M (1993) A structural polymorphism of human dopamine D2 receptor D2(Ser311–>Cys). Biochem Biophys Res Commun 196(3):1369–1375PubMedCrossRef

33.

Grandy DK, Zhang Y, Civelli O (1993) PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 2(12):2197PubMedCrossRef

34.

Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA, Potkin SG, Macciardi F, Kennedy JL (1999) Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21(1):17–27PubMedCrossRef

35.

Seaman MI, Fisher JB, Chang F, Kidd KK (1999) Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am J Med Genet 88(6):705–709PubMedCrossRef

36.

Okuyama Y, Ishiguro H, Toru M, Arinami T (1999) A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Biophys Res Commun 258(2):292–295PubMedCrossRef

37.

Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (2001) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350(6319):610–614

38.

Sano A, Kondoh K, Kakimoto Y, Kondo I (1993) A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 91(4):405–406PubMedCrossRef

39.

Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRef

40.

Stephens M, Donnelly P (2001) Comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(6):1162–1169

41.

Cavalli-Sforza LL, Menozzi P, Piazza A (1994) The history and geography of human genes. Princeton University Press, Princeton, NJ, pp 19–20, 101–102, 238–242

42.

Passarino G, Semino O, Bernini LF, Santachiara-Benerecetti AS (1996) Pre-Caucasoid and Caucasoid genetic features of the Indian population, revealed by mtDNA polymorphisms. Am J Hum Genet 59(4):927–934PubMed

43.

D’Souza UM, Russ C, Tahir E, Mill J, McGuffin P, Asherson PJ, Craig IW (2004) Functional effects of a tandem duplication polymorphism in the 5′flanking region of the DRD4 gene. Biol Psychiatry 56(9):691–697PubMedCrossRef

Title: Genetic susceptibility to Parkinson’s disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker
Authors: Ramesh C. Juyal
Mitashree Das
Sohan Punia
Madhuri Behari
Geetika Nainwal
Sumit Singh
Pazhayannur V. Swaminath
Shyla T. Govindappa
Sachi Jayaram
Uday B. Muthane
B. K Thelma
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: Neurogenetics / Issue 4/2006
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-006-0048-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetic susceptibility to Parkinson’s disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2006

Microcephaly and simplified gyral pattern of the brain associated with early onset insulin-dependent diabetes mellitus

The A431E mutation in PSEN1 causing Familial Alzheimer’s Disease originating in Jalisco State, Mexico: an additional fifteen families

Behavior of mice with mutations in the conserved region deleted in velocardiofacial/DiGeorge syndrome

Mitochondrial DNA sequence variation and mutation rate in patients with CADASIL

Acknowledgement to Referees 2005–2006

Mutations in the CLCN2 gene are a rare cause of idiopathic generalized epilepsy syndromes